Autoimmune responses associated with SARS-CoV-2 infection

与 SARS-CoV-2 感染相关的自身免疫反应

基本信息

项目摘要

PROJECT SUMMARY Current research focuses on three important aspects of COVID-19 pandemic – therapy, vaccine and diagnostics. Directing UPMC's Clinical Immune Diagnostic Laboratory, we understand the urgent need to initiate clinical research that will allow us to assess and analyze potential deferred health outcomes in a population of recovered COVID-19 patients. Although a robust immune response is associated with clinical recovery of most SARS-CoV- 2 infected patients, when a protective immune response is impaired or delayed, virus will propagate, and massive destruction of the affected tissues will occur. Extensive tissue damage and release of autoantigens, especially if associated with disproportionate systemic inflammation and cytokine storm, has been shown to dysregulate peripheral immune tolerance and facilitate initiation of autoimmune pathways. Our working hypothesis that COVID-19 recovered individuals are under increased risk of developing antibodies to self-antigen(s) is a high- risk hypothesis with important clinical implications that will lay the groundwork for future mechanistic studies. To test our hypothesis, we propose to: Determine if increased autoantibodies are associated with prior SARS-CoV- 2 infection by measuring prevalence of autoantibodies in patients with a history of COVID-19 infection. If our hypothesis is confirmed, our data will provide the first evidence for the need to follow COVID-19 recovered patients for the appearance of autoimmune antibodies and increased risk of systemic and tissue-specific autoimmune diseases.
项目摘要 目前的研究集中在COVID-19大流行的三个重要方面-治疗,疫苗和诊断。 作为UPMC临床免疫诊断实验室的负责人,我们了解开展临床免疫诊断的迫切需要。 这项研究将使我们能够评估和分析康复人群中潜在的延迟健康结果, 2019冠状病毒病患者。尽管强有力的免疫应答与大多数SARS-CoV的临床恢复有关, 2感染患者,当保护性免疫反应受损或延迟时,病毒将繁殖,并大量传播。 将发生受影响组织的破坏。广泛的组织损伤和自身抗原的释放,特别是如果 与不成比例的全身性炎症和细胞因子风暴有关, 外周免疫耐受和促进启动自身免疫途径。我们的假设是 COVID-19康复者产生自身抗原抗体的风险增加, 具有重要临床意义的风险假设,将为未来的机制研究奠定基础。到 为了验证我们的假设,我们建议:确定增加的自身抗体是否与先前的SARS-CoV相关- 通过测量有COVID-19感染史的患者中自身抗体的患病率来评估2型感染。如果我们的 假设得到证实,我们的数据将为需要跟踪COVID-19恢复提供第一个证据 患者自身免疫抗体的出现以及全身性和组织特异性 自身免疫性疾病

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sarah E. Wheeler其他文献

Pharmacokinetic and clinical outcomes when ideal body weight is used to dose busulfan in obese hematopoietic stem cell transplant recipients
在肥胖造血干细胞移植受者中使用理想体重给药白消安时的药代动力学和临床结果
  • DOI:
  • 发表时间:
    2018
  • 期刊:
  • 影响因子:
    4.8
  • 作者:
    Shawn P Griffin;Sarah E. Wheeler;L. Wiggins;H. Murthy;Jack W. Hsu;A. Richards
  • 通讯作者:
    A. Richards
Escape the Pipeline Decline: Integrating a Virtual Pharmacy Escape Quest into High School Classrooms
  • DOI:
    10.1016/j.ajpe.2024.100973
  • 发表时间:
    2024-09-01
  • 期刊:
  • 影响因子:
  • 作者:
    Sarah E. Wheeler;Leeann Williamson;Katelyn M. Sanders
  • 通讯作者:
    Katelyn M. Sanders
Glycemic relapse in a collaborative primary care-based type 2 diabetes management program.
基于协作初级保健的 2 型糖尿病管理计划中的血糖复发。
  • DOI:
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    2.1
  • 作者:
    Sarah E. Wheeler;Tamara Struebing;R. Drury;L. Caruso;Bingxiang Teng;R. Brazauskas;Ryan Hanson;Bradley H. Crotty
  • 通讯作者:
    Bradley H. Crotty
Correction: Mu heavy chain disease with MYD88 L265P mutation: An unusual manifestation of lymphoplasmacytic lymphoma
  • DOI:
    10.1186/s13000-022-01265-w
  • 发表时间:
    2022-10-20
  • 期刊:
  • 影响因子:
    2.300
  • 作者:
    Vandana Baloda;Sarah E. Wheeler;David L. Murray;Mindy C. Kohlhagen;Jeffrey A. Vos;Svetlana A. Yatsenko;Mounzer E. Agha;Miroslav Djokic;Steven H. Swerdlow;Nathanael G. Bailey
  • 通讯作者:
    Nathanael G. Bailey
Updates in the use of targeted therapies for the treatment of cholangiocarcinoma
胆管癌靶向治疗的最新进展

Sarah E. Wheeler的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sarah E. Wheeler', 18)}}的其他基金

Autoimmune responses associated with SARS-CoV-2 infection
与 SARS-CoV-2 感染相关的自身免疫反应
  • 批准号:
    10611414
  • 财政年份:
    2022
  • 资助金额:
    $ 22.29万
  • 项目类别:
EGFRvIII expression, signaling and treatment in SCC of the head and neck
头颈部鳞状细胞癌中 EGFRvIII 的表达、信号传导和治疗
  • 批准号:
    8100179
  • 财政年份:
    2010
  • 资助金额:
    $ 22.29万
  • 项目类别:
EGFRvIII expression, signaling and treatment in SCC of the head and neck
头颈部鳞状细胞癌中 EGFRvIII 的表达、信号传导和治疗
  • 批准号:
    8000381
  • 财政年份:
    2010
  • 资助金额:
    $ 22.29万
  • 项目类别:

相似海外基金

Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.29万
  • 项目类别:
    Research Grant
The Association Between Aging, Inflammation, and Clinical Outcomes in Acute Respiratory Distress Syndrome
衰老、炎症与急性呼吸窘迫综合征临床结果之间的关联
  • 批准号:
    10722669
  • 财政年份:
    2023
  • 资助金额:
    $ 22.29万
  • 项目类别:
Sedatives Pharmacology in Acute Respiratory Distress Syndrome- SPA
急性呼吸窘迫综合征中的镇静药理学 - SPA
  • 批准号:
    491387
  • 财政年份:
    2023
  • 资助金额:
    $ 22.29万
  • 项目类别:
    Fellowship Programs
New mechanism-based TREM-1 therapy for acute respiratory distress syndrome
基于新机制的 TREM-1 疗法治疗急性呼吸窘迫综合征
  • 批准号:
    10678788
  • 财政年份:
    2023
  • 资助金额:
    $ 22.29万
  • 项目类别:
Great Lakes Clinical Center of the Acute Respiratory Distress Syndrome, Pneumonia and Sepsis (APS) Consortium
急性呼吸窘迫综合征、肺炎和败血症 (APS) 联盟五大湖临床中心
  • 批准号:
    10646578
  • 财政年份:
    2023
  • 资助金额:
    $ 22.29万
  • 项目类别:
Effect of ADAMTS13 on pathogenesis of acute respiratory distress syndrome
ADAMTS13 对急性呼吸窘迫综合征发病机制的影响
  • 批准号:
    23K08447
  • 财政年份:
    2023
  • 资助金额:
    $ 22.29万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)
一种新型合成生物学衍生的微生物疗法,可治疗病毒引起的急性呼吸窘迫综合征(ARDS)
  • 批准号:
    10601865
  • 财政年份:
    2023
  • 资助金额:
    $ 22.29万
  • 项目类别:
Development of drug therapy targeting ferroptosis, iron-dependent cell death for acute respiratory distress syndrome.
开发针对铁死亡(急性呼吸窘迫综合征的铁依赖性细胞死亡)的药物疗法。
  • 批准号:
    23K08360
  • 财政年份:
    2023
  • 资助金额:
    $ 22.29万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Sustainable Implementation of Prone Positioning for the Acute Respiratory Distress Syndrome
持续实施俯卧位治疗急性呼吸窘迫综合征
  • 批准号:
    10722194
  • 财政年份:
    2023
  • 资助金额:
    $ 22.29万
  • 项目类别:
Point-of-care system to assess the risk of trauma-induced acute respiratory distress syndrome
用于评估创伤引起的急性呼吸窘迫综合征风险的护理点系统
  • 批准号:
    10594793
  • 财政年份:
    2023
  • 资助金额:
    $ 22.29万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了